查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1844085

心臟衰竭POC 和 LOC 设备市场（按测试类型、设备类型、技术和最终用户划分）- 全球预测，2025 年至 2032 年

Heart Failure POC & LOC Devices Market by Test Type, Device Type, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，心臟衰竭POC 和 LOC 设备市场将成长至 7.4492 亿美元，复合年增长率为 13.67%。

主要市场统计数据
基准年2024年 2.6711亿美元
预计2025年 3.0192亿美元
预测年份：2032年 7.4492亿美元
复合年增长率（%） 13.67%

全面概述重新定义现代医疗保健中心臟衰竭的照护现场和线下诊断的技术、临床和操作趋势

技术进步、医疗服务模式的转变以及日益复杂的生物学见解的融合，使照护现场和线下诊断设备成为心臟衰竭管理的前沿。本执行摘要概述了影响临床、商业、监管和供应链领域中相关人员的最重要的发展。它强调了新兴诊断方式、设备外形规格和付款人期望如何重塑心臟衰竭的检测和监测时间、地点和方式，并概述了对製造商、医疗系统和投资者的影响。

在整个医疗保健领域，临床医生需要更快、可操作的数据来支援护理协调、分诊决策和远端监控。同时，设备製造商正在从单一分析物测试转向多路復用平台，将生物感测器和影像处理功能整合到穿戴式装置和桌上型装置中。因此，产品开发週期越来越强调互通性、资料安全性和以使用者为中心的设计，以满足急诊和社区照护的需求。以下章节重点介绍转型转变、资费主导的供应链效应以及细分市场和特定区域的洞察，最后提供可行的建议，并对用于得出我们研究结果的分析方法进行清晰的解释。

生物标记科学、感测器小型化和分散护理服务的进步如何重塑心臟衰竭患者的诊断和监测

心臟衰竭治疗正在经历变革性变革，这得益于新型生物检测、设备微型化以及注重早期疗育和纵向监测的新型护理模式的相互作用。基因组学、蛋白质组学和代谢组学检测领域的创新正在扩大临床医生可用的生物标记范围，从而能够对心臟衰竭综合征进行更细緻的表型分析，并识别出此前因临床异质性而难以识别的治疗靶点。同时，基于生物感测器的系统和成像平台正在使在传统医院环境之外进行持续或近乎即时的生理评估成为可能。

这项技术变革与不断发展的临床路径相辅相成，使诊断智慧更贴近患者。穿戴式和可携式诊断设备如今能够提供持续的生理讯号，并与实验室检测相结合，创建有助于个人化治疗方案调整的混合诊断方案。随着互通性和云原生分析技术的成熟，护理团队可以将纵向讯号与个别检测结果结合，从而更早发现病情进展，减少可避免的住院治疗。法律规范和报销机制也逐渐调整，鼓励以结果为导向的部署，并强调资料完整性、临床检验和病人安全。总而言之，这些发展预示着一个新时代的到来，在这个时代，诊断的准确性、分散式护理和数数位化将改善心臟衰竭的管理。

评估近期美国关税动态如何影响心臟衰竭诊断和监控设备的供应链弹性、采购选择和产品设计决策

美国近期的关税调整和贸易政策转变，对服务于心臟衰竭照护现场和线下诊疗市场的製造商和经销商的供应链和商业策略产生了复杂的下游影响。关税导致的零件成本上涨，可能会对依赖专用感测器、成像模组和进口试剂的设备製造商造成特别严重的衝击。因此，采购团队被迫探索替代采购管道，与供应商协商签订长期合同，并加速垂直整合，以保护利润率并确保供应的连续性。

关税不仅影响直接成本，还会影响策略选择，例如区域製造地、库存政策以及优先考虑模组化和组件标准化的产品设计决策。企业正在透过跨区域多元化供应商、确定二级製造地以及重新设计设备来应对，以最大限度地减少对关税敏感型投入的依赖。对于临床合作伙伴和医疗系统而言，这些变更可能会改变设备采购时间表，需要製定适应性采购策略，优先考虑可行的替代方案，并加速在地采购技术的临床检验。重要的是，在供应链转变期间，法规遵循和品质保证仍然是不可协商的。相关人员必须在速度与严格的临床和安全监督之间取得平衡，以维护病患信心和系统弹性。

透过对测试模式、设备外形规格、支援技术和护理环境进行分层细分，获得洞察，从而优先考虑临床检验和商业化途径

基于细分市场的洞察揭示了不同的模式和用例如何推动心臟衰竭诊断领域的研究和商业化重点。依检测类型，市场涵盖基因组学、代谢组学和蛋白​​质组学检测，每种检测都各具优势。基因组学检测有助于遗传风险和治疗反应分层，代谢组学分析可捕捉与充血和灌注相关的动态代谢异常，蛋白质组学检测可揭示与心肌压力和重塑相关的蛋白质生物标记。结合这些检测，可以建立一个多层级的诊断架构，其中分子特征与生理监测相辅相成，从而提高诊断和预后的准确性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 在照护现场心臟衰竭诊断中采用人工智慧驱动演算法进行预测风险分层
  • 开发微流体实验室晶片平台，实现心臟衰竭监测的多路復用生物标记检测
  • 将穿戴式感测器数据与照护现场设备结合，以促进心臟衰竭患者的远端系统管理
  • 基于奈米材料的生物感测器的进展提高了 LOC 系统中检测心臟衰竭标记物的灵敏度
  • 加速新兴市场创新心臟衰竭即时诊断技术核准的监管途径
  • 设备製造商和远端医疗提供者之间的协作生态系统，以增强心臟衰竭管理的连接性
  • 影响照护现场和实验室晶片设备在心臟衰竭治疗中的应用的商业化挑战和成本效益分析
  • 推出一款智慧型手机整合实验室晶片设备，可实现携带式、家用的心臟衰竭生物标记定量测量

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章。心臟衰竭POC 和 LOC 设备市场（按测试类型）

  • 基因组检测
  • 代谢体学检测
  • 蛋白质体检测

第九章：心臟衰竭POC 和 LOC 设备市场（按设备类型）

  • 诊断设备
    • 心臟生物标记分析仪
    • 心臟影像诊断设备
    • 心电图（ECG）
  • 穿戴式装置
    • 体外去心房颤动
    • 心率监测器

第 10 章。心臟衰竭POC 和 LOC 设备市场（按技术）

  • 基于生物感测器的系统
  • 基于成像和电阻的平台
  • 免疫检测
  • 基于核酸的平台

第 11 章。心臟衰竭POC 和 LOC 设备市场（按最终用户）

  • 辅助生活医疗保健
  • 居家护理设施
  • 医院和诊所
  • 实验室

第 12 章。心臟衰竭POC 和 LOC 设备市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章心臟衰竭POC 和 LOC 设备市场：按类别

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。心臟衰竭POC 和 LOC 设备市场（按国家/地区）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • ACON Laboratories Inc.
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Boston Scientific Corporation
    • Cipla Limited
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd.
    • Fukuda Denshi Co., Ltd.
    • Jant Pharmacal Corporation
    • Johari Digital India Limited by Syrma SGS
    • Koninklijke Philips NV
    • LifeSign LLC
    • LifeSync
    • Luminex Corporation by DiaSorin SpA
    • Mitsubishi Chemical Group Corporation
    • Nexus Dx, Inc
    • Nihon Kohden Corporation
    • Quidel Corporation
    • Schiller AG
    • Shenzhen EDAN Instrument Co., Ltd.
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Siemens Healthineers AG
    • Spectral Diagnostics Inc.
    • Trinity Biotech PLC
Product Code: MRR-CA17E905EA91

The Heart Failure POC & LOC Devices Market is projected to grow by USD 744.92 million at a CAGR of 13.67% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 267.11 million
Estimated Year [2025] USD 301.92 million
Forecast Year [2032] USD 744.92 million
CAGR (%) 13.67%

An integrated overview of technological, clinical, and operational trends redefining heart failure point-of-care and line-of-care diagnostics in modern healthcare

The convergence of technological advances, shifting care delivery models, and increasingly granular biological insights has placed point-of-care and line-of-care devices at the forefront of heart failure management. This executive summary synthesizes the most consequential developments affecting stakeholders across clinical, commercial, regulatory, and supply chain domains. It articulates how emerging diagnostic modalities, device form factors, and payer expectations are reshaping where, when, and how heart failure is detected and monitored, and it frames implications for manufacturers, health systems, and investors.

Across care settings, clinicians demand faster, more actionable data to support treatment adjustments, triage decisions, and remote monitoring. Concurrently, device makers are moving from single-analyte tests toward multiplexed platforms and integrating biosensor and imaging capabilities into wearable and bench devices. As a result, product development cycles increasingly emphasize interoperability, data security, and user-centered design to meet the needs of both acute care and community-based practitioners. The following sections unpack transformative shifts, tariff-driven supply chain effects, and segmentation- and region-specific insights, concluding with pragmatic recommendations and a transparent description of analytical methods used to derive the findings.

How converging advances in biomarker science, sensor miniaturization, and decentralized care delivery are reshaping diagnostics and monitoring for heart failure patients

Heart failure care is undergoing transformative shifts driven by the interplay of novel biological testing, device miniaturization, and new models of care that prioritize early intervention and longitudinal monitoring. Innovations in genomic, proteomic, and metabolomic testing are expanding the range of biomarkers available to clinicians, enabling more nuanced phenotyping of heart failure syndromes and identifying therapeutic targets previously obscured by clinical heterogeneity. In parallel, biosensor-based systems and imaging-enhanced platforms are permitting continuous or near-real-time physiologic assessment outside traditional hospital settings.

These technological shifts are complemented by evolving clinical pathways that move diagnostic intelligence closer to the patient. Wearable devices and ambulatory diagnostic devices now provide sustained physiologic signals that, when integrated with lab-based assays, create hybrid diagnostic profiles that inform personalized titration of therapies. As interoperability and cloud-native analytics mature, care teams can synthesize longitudinal signals with discrete test results to detect decompensation earlier and reduce avoidable admissions. Regulatory frameworks and reimbursement mechanisms are adapting incrementally, incentivizing outcomes-driven deployments while emphasizing data integrity, clinical validation, and patient safety. Taken together, these developments herald a new era in which diagnostic precision, care decentralization, and digital enablement converge to improve heart failure management.

Assessing how recent United States tariff dynamics are shaping supply chain resilience, sourcing choices, and product design decisions for heart failure diagnostic and monitoring devices

Recent tariff adjustments and trade policy shifts in the United States create complex downstream effects on the supply chains and commercial strategies of manufacturers and distributors serving heart failure point-of-care and line-of-care markets. Tariff-driven increases in component costs can disproportionately affect device makers that rely on specialized sensors, imaging modules, and imported assay reagents. As a result, procurement teams face pressure to seek alternative sourcing, negotiate longer-term supplier agreements, or accelerate vertical integration to preserve margin and ensure continuity of supply.

Beyond direct cost implications, tariffs influence strategic choices such as regional manufacturing footprints, inventory policy, and product design decisions that favor modularity and component standardization. Companies are responding by diversifying suppliers across geographies, qualifying secondary manufacturing sites, and redesigning devices to minimize reliance on tariff-sensitive inputs. For clinical partners and health systems, these changes may alter device availability timelines and necessitate adaptive purchasing strategies that prioritize validated alternatives and accelerate clinical validation of locally sourced technologies. Importantly, regulatory compliance and quality assurance remain non-negotiable during supply chain shifts, and stakeholders must balance speed with rigorous clinical and safety oversight to maintain patient trust and system resilience.

Insights informed by layered segmentation of test modalities, device form factors, enabling technologies, and care settings to prioritize clinical validation and commercialization pathways

Segmentation-driven insight reveals how different modalities and use cases are steering research and commercialization priorities within the heart failure diagnostic landscape. Based on test type, the market is studied across genomic testing, metabolomic testing, and proteomic testing, each offering distinct advantages: genomic approaches help stratify inherited risk and therapy response, metabolomic profiling captures dynamic metabolic derangements linked to congestion and perfusion, and proteomic assays illuminate protein biomarkers that correlate with myocardial stress and remodeling. Together, these test types support a layered diagnostic architecture in which molecular signatures complement physiologic monitoring to refine diagnosis and prognostication.

Based on device type, the market is studied across diagnostic devices and wearable devices. Diagnostic devices are further studied across cardiac biomarker analyzers, cardiac imaging devices, and electrocardiogram (ECG) systems. Cardiac biomarker analyzers enable point-of-care quantification of peptides and enzymes critical for acute assessment, while compact imaging and impedance platforms extend structural and hemodynamic evaluation to non-traditional settings. Electrocardiogram systems remain foundational for rhythm and conduction assessment and are increasingly integrated into multimodal diagnostic suites. Wearable devices are further studied across external defibrillators and heart rate monitors, reflecting a spectrum that ranges from life-saving emergency interventions to continuous physiologic surveillance that supports early intervention.

Based on technology, the market is studied across biosensor-based systems, imaging & impedance-based platforms, immunoassays, and nucleic acid-based platforms. Biosensor-based systems drive continuous, minimally invasive monitoring; imaging and impedance technologies add structural and fluid status context; immunoassays provide rapid protein-based quantification; and nucleic acid platforms facilitate precision-level molecular diagnostics. Based on end user, the market is studied across assisted living healthcare, home care facilities, hospitals & clinics, and laboratory settings, each with unique operational constraints, staffing models, and data integration requirements. When considered together, these segmentation layers reveal where investment and clinical validation should concentrate to create interoperable, clinically actionable diagnostic pathways across care environments.

Regional adoption patterns and regulatory heterogeneity across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence commercialization strategies and clinical deployment

Regional dynamics materially influence device adoption patterns, regulatory approaches, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems increasingly emphasize outpatient management and value-based initiatives that create demand for rapid, actionable diagnostics and remote monitoring solutions. This environment favors devices and platforms that integrate with electronic medical records and support care-coordination workflows, as well as those that demonstrate impact on readmissions and resource utilization.

Across Europe, Middle East & Africa, diverse regulatory landscapes and reimbursement models shape adoption heterogeneously. High-income European markets often prioritize clinical validation and interoperability standards, while resource-constrained settings focus on cost-effectiveness and robustness. As a result, manufacturers must tailor market-entry strategies to local regulatory requirements and demonstrate pragmatic benefits in both tertiary centers and community settings. In the Asia-Pacific region, rapid adoption of digital health, large population cohorts, and growing local manufacturing capacity generate opportunities for scalable deployments of biosensor-enabled wearables and compact diagnostic devices. Strategic partnerships with regional distributors and clinical networks accelerate validation and uptake, while localization efforts in design and service support enhance user adoption. Across all regions, data governance, privacy compliance, and supply chain stability remain critical considerations for successful commercialization.

Analyzing competitive forces where incumbent manufacturers, diagnostics innovators, and tech-enabled entrants converge to form partnerships and differentiate through clinical evidence and service models

Competitive dynamics in the heart failure point-of-care and line-of-care space reflect a mix of established medical device firms, specialized diagnostics developers, and technology-focused entrants that blend hardware, assays, and analytics. Established device manufacturers leverage legacy relationships with health systems and supply chain scale to distribute diagnostic devices and integrated platforms, while smaller innovators focus on niche biologic assays, novel biosensors, and software-enabled monitoring solutions that prioritize user experience and connectivity.

Collaborations between device makers and clinical research networks are increasingly common because co-development helps accelerate real-world validation and payer engagement. Strategic alliances, licensing arrangements, and OEM partnerships enable rapid scaling while preserving clinical credibility. Additionally, the integration of analytics and cloud services creates new value propositions around predictive maintenance, population health management, and remote patient management. As a result, companies that can demonstrate clinical utility, regulatory compliance, and secure data interoperability gain a competitive advantage. Supply chain adaptability, modular product architectures, and the ability to offer bundled hardware-plus-service models further distinguish market leaders from niche players. Ultimately, the competitive landscape rewards organizations that align rigorous clinical evidence generation with nimble commercial execution and robust post-market support.

Practical strategic actions for manufacturers and health system leaders to accelerate adoption, strengthen supply resilience, and align evidence generation with payer priorities

Industry leaders should prioritize a set of actionable measures that accelerate clinical adoption and safeguard commercial resilience. First, align product development with clinically meaningful endpoints and pragmatic trial designs that reflect real-world workflows and demonstrate outcomes that matter to payers and providers. This focus reduces time-to-adoption friction and strengthens reimbursement discussions. Second, invest in supply chain diversification and component standardization to reduce exposure to tariff shocks and geopolitical disruption. Dual-sourcing critical components and qualifying alternate manufacturing sites will enhance continuity and enable more predictable delivery schedules.

Third, design devices and software with interoperability and cybersecurity by default, ensuring seamless integration with electronic health records and remote monitoring platforms while protecting patient data. Fourth, pursue strategic partnerships with care networks and home health providers to validate care models that leverage diagnostic and wearable combinations, enabling smoother commercialization pathways. Fifth, adopt flexible commercial models that combine device sales with subscription-based analytics and service agreements to create recurring revenue and deeper system integration. Finally, maintain an active engagement with regulators and payers to shape pragmatic evidence requirements and to accelerate pathways for reimbursement that reflect real-world value.

Transparent description of the research approach integrating primary interviews, literature synthesis, and scenario analysis to derive actionable insights without relying on numerical market forecasts

This analysis synthesizes primary interviews with clinical leaders, device manufacturers, supply chain experts, and regulatory advisors, complemented by a systematic review of peer-reviewed literature and public regulatory guidance relevant to heart failure diagnostics and monitoring. Primary qualitative input focused on clinical workflows, device usability, sourcing strategies, and commercialization hurdles. Secondary sources provided technical context on biosensor technologies, assay performance characteristics, and recent policy shifts influencing trade and reimbursement. The methodology prioritized triangulation to validate emergent themes across multiple data sources and to surface actionable insights rather than raw market estimates.

Analytical steps included mapping the diagnostic and device ecosystem by test type, device form factor, enabling technology, and end-user environment to reveal where clinical need and technical feasibility align. Scenario analysis explored supply chain responses to tariff and trade policy changes, emphasizing operational strategies that preserve quality and continuity. Evidence synthesis highlighted recurring barriers to adoption-such as integration burden, clinical validation gaps, and reimbursement uncertainty-and identified levers for acceleration including strategic partnerships, localized manufacturing, and flexible commercial models. Wherever applicable, findings were cross-validated with domain experts to ensure relevance and practical applicability for decision-makers.

Synthesis of how innovation, clinical validation, and resilient commercialization strategies must converge to turn diagnostic and monitoring advances into tangible improvements in heart failure care

The landscape of heart failure point-of-care and line-of-care devices is marked by rapid technical innovation, evolving care models, and heightened sensitivity to supply chain and policy dynamics. New molecular tests and biosensor-enabled monitoring are expanding diagnostic possibilities, while modular device architectures and data-driven services are redefining commercial value. Concurrent pressures from trade policy and tariff changes underscore the need for resilient sourcing and adaptive manufacturing strategies that do not compromise clinical quality or regulatory compliance.

Looking ahead, stakeholders who integrate rigorous clinical validation with pragmatic commercialization approaches and robust supply chain planning will be best positioned to capture clinical trust and operational scale. Cross-sector collaboration among manufacturers, care providers, payers, and regulators remains essential to translate technological promise into sustained improvements in patient outcomes. By focusing on interoperability, evidence generation tied to meaningful clinical endpoints, and flexible deployment models suited to regional contexts, organizations can accelerate the adoption of diagnostic and wearable solutions that meaningfully improve heart failure management across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven algorithms in point-of-care heart failure diagnostics for predictive risk stratification
  • 5.2. Development of microfluidic lab-on-chip platforms enabling multiplexed biomarker detection for heart failure monitoring
  • 5.3. Integration of wearable sensor data with point-of-care devices to facilitate remote heart failure patient management
  • 5.4. Advancements in nanomaterial-based biosensors for increasing sensitivity of heart failure marker detection in LOC systems
  • 5.5. Regulatory pathways accelerating the approval of innovative heart failure point-of-care diagnostic technologies in emerging markets
  • 5.6. Collaborative ecosystem between device manufacturers and telehealth providers enhancing connectivity for heart failure management
  • 5.7. Commercialization challenges and cost-effectiveness analyses influencing adoption of point-of-care and lab-on-chip devices in heart failure care
  • 5.8. Emergence of smartphone-integrated lab-on-chip devices offering portable heart failure biomarker quantification at-home use

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Failure POC & LOC Devices Market, by Test Type

  • 8.1. Genomic Testing
  • 8.2. Metabolomic Testing
  • 8.3. Proteomic Testing

9. Heart Failure POC & LOC Devices Market, by Device Type

  • 9.1. Diagnostic Devices
    • 9.1.1. Cardiac Biomarker Analyzers
    • 9.1.2. Cardiac Imaging Devices
    • 9.1.3. Electrocardiogram (ECG)
  • 9.2. Wearable Devices
    • 9.2.1. External Defibrillator
    • 9.2.2. Heart Rate Monitors

10. Heart Failure POC & LOC Devices Market, by Technology

  • 10.1. Biosensor-based systems
  • 10.2. Imaging & impedance-based platforms
  • 10.3. Immunoassays
  • 10.4. Nucleic acid-based platforms

11. Heart Failure POC & LOC Devices Market, by End User

  • 11.1. Assisted Living Healthcare
  • 11.2. Home Care Facilities
  • 11.3. Hospitals & Clinics
  • 11.4. Laboratory

12. Heart Failure POC & LOC Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Heart Failure POC & LOC Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Heart Failure POC & LOC Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. ACON Laboratories Inc.
    • 15.3.3. Becton, Dickinson and Company
    • 15.3.4. Bio-Rad Laboratories, Inc.
    • 15.3.5. bioMerieux S.A.
    • 15.3.6. Boston Scientific Corporation
    • 15.3.7. Cipla Limited
    • 15.3.8. Danaher Corporation
    • 15.3.9. F. Hoffmann-La Roche Ltd.
    • 15.3.10. Fukuda Denshi Co., Ltd.
    • 15.3.11. Jant Pharmacal Corporation
    • 15.3.12. Johari Digital India Limited by Syrma SGS
    • 15.3.13. Koninklijke Philips N.V.
    • 15.3.14. LifeSign LLC
    • 15.3.15. LifeSync
    • 15.3.16. Luminex Corporation by DiaSorin S.p.A.
    • 15.3.17. Mitsubishi Chemical Group Corporation
    • 15.3.18. Nexus Dx, Inc
    • 15.3.19. Nihon Kohden Corporation
    • 15.3.20. Quidel Corporation
    • 15.3.21. Schiller AG
    • 15.3.22. Shenzhen EDAN Instrument Co., Ltd.
    • 15.3.23. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 15.3.24. Siemens Healthineers AG
    • 15.3.25. Spectral Diagnostics Inc.
    • 15.3.26. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HEART FAILURE POC & LOC DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HEART FAILURE POC & LOC DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEART FAILURE POC & LOC DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 262. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 263. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 264. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 265. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. GCC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2024 (USD MI